Coverage

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more